Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

heparin/inflammation

リンクがクリップボードに保存されます
ページ 1 から 41 結果

Heparin cofactor II fragments with anti-inflammatory and anti-coagulant activity

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Phase application under 35 U.S.C. .sctn.371 of International Application No. PCT/GB2010/001780 filed Sep. 21, 2010 and claims the benefit of Great Britain Application No. 0916578.8 filed Sep. 22, 2009, the disclosures of which

Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND OF THE INVENTION Glycosaminoglycans, a ubiquitous class of sulfated polysaccharides, play a critical role in various physiological processes, such as development, wound healing, angiogenesis, cell division, inflammation and spinal cord injury. The complexity of this class of natural

Therapeutic methods of using O-desulfated heparin derivatives

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION This invention relates to O-desulfated heparin compositions and methods of making the same, preferably 6-O-desulfated heparin compositions, wherein the methods permit regulating the degree of 6-O-desulfation. The compositions are useful for treating various diseases, including

Pharmaceutical compositions for the oral administration of heparin or derivatives thereof

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
This application is the U.S. national phase of international application PCT/EP02/13651, filed 3 Dec. 2002, which designated the U.S. The present invention relates to pharmaceutical compositions suitable for the oral administration of heparin or derivatives thereof for the treatment of inflammatory

Pharmaceutical compositions for the oral administration of heparin or derivatives thereof

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The present invention relates to pharmaceutical compositions suitable for the oral administration of heparin or derivatives thereof, for example dalteparin, salts and/or derivatives thereof, for the treatment of inflammatory bowel diseases. More particularly, the invention relates to

Use of heparinases to decrease inflammatory response

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION This invention is in the field of medical treatments and is directed to the use of heparinase enzyme as a treatment or prophylactic for reducing localized inflammatory responses. BACKGROUND OF THE INVENTION An inflammatory response is local response to cellular injury that is

Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND OF THE INVENTION The adhesion of mammalian cells to the extracellular matrix is of fundamental importance in regulating growth, adhesion, motility and the development of proper cellular phenotype. This has implications for normal development, wound healing, immunity, chronic inflammatory

Macrophage inflammatory protein 2 (MIP-2)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
RELATED PUBLICATIONS The Applicants are authors or co-authors of several articles directed to the subject matter of the present invention. These articles supplement those articles listed in U.S. Pat. No. 4,603,106, which earlier articles are incorporated herein by reference. (1) [Applicant Cerami

Macrophage-derived inflammatory mediator (MIP-2)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
RELATED PUBLICATIONS The Applicants are authors or co-authors of several articles directed to the subject matter of the present invention. These articles supplement those articles listed in U.S. Pat. No. 4,603,106, which earlier articles are incorporated herein by reference. (1) [Applicant Cerami

Composition comprising an antibody to macrophage-derived inflammatory mediator (MIP-2)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
RELATED PUBLICATIONS The Applicants are authors or co-authors of several articles directed to the subject matter of the present invention. These articles supplement those articles listed in U.S. Pat. No. 4,603,106, which earlier articles are incorporated herein by reference. (1) [Applicant Cerami

Antibody to macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
RELATED PUBLICATIONS The Applicants are authors or co-authors of several articles directed to the subject matter of the present invention. These articles are in supplementation to those articles listed in U.S. Pat. No. 4,603,106, which earlier articles are incorporated herein by reference. (1)

Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
RELATED PUBLICATIONS The Applicants are authors or co-authors of several articles directed to the subject matter of the present invention. These articles are in supplementation to those articles listed in U.S. Pat. No. 4,603,106, which earlier articles are incorporated herein by reference. (1)

Macrophage-derived inflammatory mediator (MIP-1 .alpha. and MIP-1 .beta.)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
RELATED PUBLICATIONS The Applicants are authors or co-authors of several articles directed to the subject matter of the present invention. These articles are in supplementation to those articles listed in U.S. Pat. No. 4,603,106, which earlier articles are incorporated herein by reference. (1)

Composition comprising antibody to macrophage-derived inflammatory mediator (MIP-.alpha. 1 and MIP-1.beta.)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
RELATED PUBLICATIONS The Applicants are authors or co-authors of several articles directed to the subject matter of the present invention. These articles are in supplementation to those articles listed in U.S. Pat. No. 4,603,106, which earlier articles are incorporated herein by reference. (1)

Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
RELATED PUBLICATIONS The Applicants are authors or co-authors of several articles directed to the subject matter of the present invention. These articles are in supplementation to those articles listed in U.S. Pat. No. 4,603,106, which earlier articles are incorporated herein by reference. (1)
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge